← back to search

Keith D. Eaton

University of Washington · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Head and Neck Cancer Studies, Cancer Immunotherapy and Biomarkers, and Lung Cancer Diagnosis and Treatment.
h-index
30
citations
12,303
works
166
NIH funding
primary concept
Medicine
email

Recent publications

Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions
Science Advances 2024cited by 27position: middledoi
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Annals of Oncology 2023cited by 84position: middledoi
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study
Clinical Lung Cancer 2023cited by 23position: middledoi
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
Investigational New Drugs 2022cited by 41position: middledoi
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
Journal of Thoracic Oncology 2016cited by 53position: middledoi
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
European Journal of Cancer 2015cited by 268position: middledoi
Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens
Journal of Molecular Diagnostics 2013cited by 279position: middledoi
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
New England Journal of Medicine 2012cited by 7,974position: middledoi
Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology 2012cited by 17position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ramaswamy Govindan · Huntsman Cancer Institute2 papers (2012–2016)Richard C. Chao · Mirati Therapeutics (United States)2 papers (2022–2023)Sai‐Hong Ignatius Ou · University of California, Irvine Medical Center2 papers (2012–2016) · 2 papers (2012–2016)Francisco Robert · University of Alabama at Birmingham2 papers (2012–2016)Weiwei Tan · Nanchang University2 papers (2012–2016)Alain C. Mita · Cedars-Sinai Medical Center2 papers (2012–2016)Gregory A. Otterson · Johns Hopkins University2 papers (2012–2016)Athanassios Argiris · Hygeia Hospital2 papers (2012–2016) · 2 papers (2012–2016)Martin Gutierrez · Hackensack University Medical Center2 papers (2012–2016)Tiziana Usari · Pfizer (Italy)2 papers (2012–2016)Edward B. Garon · Cancer Clinic2 papers (2015–2023)Rebecca S. Heist · Harvard University1 papers (2022–2022)Byoung Chul Cho · Université Grenoble Alpes1 papers (2022–2022) · 1 papers (2015–2015)Henry U. Arnold · Huntsman Cancer Institute1 papers (2024–2024)Anna-Lisa Doebley · University of Washington1 papers (2024–2024) · 1 papers (2013–2013) · 1 papers (2015–2015)